认识到真菌感染的全球负担日益增加,世界卫生组织建立了制定真菌病原体优先清单(FPPL)的程序。在这次系统审查中,我们旨在评估镰刀菌感染的流行病学和影响。,Scedosporiumspp.,和Lomentosporaprolificans通知第一个FPPL。搜索PubMed和WebofSciences数据库,以确定2011年1月1日至2021年2月23日之间发表的报告死亡率的研究。并发症和后遗症,抗真菌药敏,可预防性,年发病率,和趋势。总的来说,镰刀菌属包括20、11和9篇文章。,Scedosporiumspp.,和L.prolificans,分别。侵袭性镰刀菌病的死亡率很高,scedosporiosis,和lomentosporiosis(42.9%-66.7%,42.4%-46.9%,50.0%-71.4%,分别)。抗真菌药敏数据,基于小的隔离数,对于大多数目前可用的抗真菌剂,显示出高的最低抑制浓度(MIC)/最低有效浓度。对于所有三种病原体,伊曲康唑和伊沙武康唑的中位/模式MIC均≥16mg/l。根据有限的数据,这些真菌正在出现。侵袭性镰刀菌病在2000-2009年和2010-2015年期间分别从0.08例/10万入院增加到0.22例/10万入院。在肺移植接受者中,Scedosporiumspp.仅从2014年起检测到产乳杆菌。全球监测以更好地描述抗真菌药物的易感性,危险因素,后遗症,结果是必需的。
Recognizing the growing global burden of fungal infections, the World Health Organization established a process to develop a priority list of fungal pathogens (FPPL). In this systematic review, we aimed to evaluate the epidemiology and impact of infections caused by Fusarium spp., Scedosporium spp., and Lomentospora prolificans to inform the first FPPL. PubMed and Web of Sciences databases were searched to identify studies published between January 1, 2011 and February 23, 2021, reporting on mortality, complications and sequelae, antifungal susceptibility, preventability, annual incidence, and trends. Overall, 20, 11, and 9 articles were included for Fusarium spp., Scedosporium spp., and L. prolificans, respectively. Mortality rates were high in those with invasive
fusariosis, scedosporiosis, and lomentosporiosis (42.9%-66.7%, 42.4%-46.9%, and 50.0%-71.4%, respectively). Antifungal susceptibility data, based on small isolate numbers, showed high minimum inhibitory concentrations (MIC)/minimum effective concentrations for most currently available antifungal agents. The median/mode MIC for itraconazole and isavuconazole were ≥16 mg/l for all three pathogens. Based on limited data, these fungi are emerging. Invasive
fusariosis increased from 0.08 cases/100 000 admissions to 0.22 cases/100 000 admissions over the time periods of 2000-2009 and 2010-2015, respectively, and in lung transplant recipients, Scedosporium spp. and L. prolificans were only detected from 2014 onwards. Global surveillance to better delineate antifungal susceptibility, risk factors, sequelae, and outcomes is required.